Pregablin for Anxiety-comorbidity in Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
SchizophreniaAnxiety-comorbidity to Schizophrenia
Interventions
DRUG

Pregabalin

Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.

DRUG

Pregabalin Placebo Capsules

Parallel to Active Comparator

Trial Locations (1)

9220

Aalborg University Hospital, Psychiatry, Aalborg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Albert Einstein College of Medicine

OTHER

collaborator

GCP-unit at Aarhus University Hospital, Aarhus, Denmark

OTHER

collaborator

The Hospital Pharmcacy North Denmark Region, Denmark

UNKNOWN

collaborator

Pfizer

INDUSTRY

lead

University of Aarhus

OTHER

NCT01496690 - Pregablin for Anxiety-comorbidity in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter